Cancer Genetics Announces Strong Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Cancer Genetics (CGIX) Reports In-Line Q2 EPS
August 11, 2015 7:34 AM EDTCancer Genetics (NASDAQ: CGIX) reported Q2 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.67 million.
For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.
... More